Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study by Emiko Otsuka (7519313)

“…TSH levels were significantly decreased from a median of 2.46 (interquartile range:1.60–4.51) mU/L before roxadustat treatment to 1.36 (0.72–2.41) mU/L during treatment (<i>p</i> < 0.001), and improved to 2.56 (1.78–4.63) mU/L after halting roxadustat (<i>p</i> < 0.001). …”

Data Sheet 1_Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.docx by Yunhua Zhang (231470)

“…</p>Results<p>Within our study population, findings demonstrated a significantly decreased OS (HR: 2.02, 95% CI: 1.08–3.77, p = 0.027) and PFS (HR: 1.84, 95% CI: 1.05–3.21, p = 0.032) in HCC patients with a high baseline spleen volume, compared to individuals with lower spleen volumes. …”

Effects of berry consumption on cardiometabolic risk factors in patients with metabolic syndrome: a systematic review and meta-analysis of randomised controlled trials by Mohammad Amin Mohammadi (21440815)

“…The subgroup analysis showed that interventions <12 weeks resulted in a significant increase in HDL-C levels and a significant decrease in serum TG levels. …”

Dynamic functional connectivity changes in left DLPFC-tDCS protocol (F3a-Fp2c). by Yanqing Dong (8829548)

“…Warmer colors indicate an increase in FC, while cooler colors indicate a decrease in FC. Color bars indicate statistical t-values ().…”

Table2_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.xlsx by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Image1_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.tif by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Table4_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.xlsx by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Table5_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.xlsx by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Image2_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.tif by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Table1_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.xlsx by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Table3_Causal relationship between antihypertensive drugs and Hashimoto’s thyroiditis: a drug-target Mendelian randomization study.xlsx by Bing Cui (179696)

“…Moreover, genetically mimicking the use of loop diuretics (OR [95% CI]: 0.94 [0.91, 0.97]; p = 3.57×10^-5) and thiazide diuretics (0.98 [0.96, 0.99]; p = 3.83×10^-3) showed a significant association with a decreased risk of HT only in European population. …”

Table4_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Image1_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.JPEG by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Table3_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Image2_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.JPEG by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Table1_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Image3_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.JPEG by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

Table2_Efficacy and safety of guanxinshutong capsule combined with western medicine on stable angina pectoris: a systematic review and meta-analysis.DOC by Liyuan Yu (5341841)

“…GXST and WM combination was significantly more effective than WM alone across several metrics: clinical efficacy rate (odds ratio [OR] = 4.05, 95% confidence interval [CI] = 3.42–4.80), electrocardiogram improvement (OR = 3.39, 95% CI = 2.35–4.87), enhancement in left ventricular ejection fraction (mean difference [MD] = 1.07, 95% CI = 0.69–1.46), reduction in total cholesterol levels (MD = −0.78, 95% CI = −1.20 to −0.35), decrease in tumor necrosis factor-alpha (MD = −1.36, 95% CI = −2.18 to −0.53), and improvement in Chinese medicine evidence score (OR = 3.77, 95% CI = 2.20–6.43). …”

CoA administration prevents ISC dysfunction through antioxidative ability and protects ISCs from stress-induced DNA damage. by Zhiming Liu (216751)

“…(L) A summary model showed a decrease in activity within the pantothenate/CoA route in ISCs from older flies. …”

Supplementary file 1_Potential interactions between traditional Chinese medicine and osimertinib: a Case Report.docx by Min Zhang (111999)

“…<p>Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. …”